Banque Pictet & Cie’s Catalyst Pharmaceutical CPRX Stock Holding History

Banque Pictet & Cie’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,429	Closed	-$407K	–	409
2025 Q4	$407K	Sell	17,429 -4,098	-19%	-$91.3K	﹤0.01%	318
2025 Q3	$424K	Sell	21,527 -137	-0.6%	-$2.82K	﹤0.01%	334
2025 Q2	$470K	Sell	21,664 -1,457	-6%	-$34.4K	﹤0.01%	291
2025 Q1	$561K	Buy	+23,121	New	+$521K	﹤0.01%	284

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Banque Pictet & Cie's CPRX Position: Q1 2026 in Review

Banque Pictet & Cie sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 17,429 shares — an estimated $407K sold.

Banque Pictet & Cie first reported a position in CPRX in Q1 2025 and held it in 4 quarters. The position peaked at $561K in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Banque Pictet & Cie reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Banque Pictet & Cie sold 17,429 Catalyst Pharmaceutical shares in Q1 2026, an estimated $407K.
Banque Pictet & Cie first reported a position in Catalyst Pharmaceutical in Q1 2025 and held it in 4 quarters.
Banque Pictet & Cie's Catalyst Pharmaceutical position peaked at $561K in Q1 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Banque Pictet & Cie's 13F filing for Q1 2026, filed 14 Apr 2026.